AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects (JSAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00970775
Recruitment Status : Completed
First Posted : September 2, 2009
Last Update Posted : March 18, 2010
Information provided by:

Brief Summary:
This is a Phase I, single centre, randomised, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability and pharmacokinetics of AZD2423 following single ascending dose administration to healthy Japanese subjects.

Condition or disease Intervention/treatment Phase
Healthy Volunteer Drug: AZD2423 Drug: Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 After Single Ascending Doses in Healthy Japanese Male and Non-Fertile Female Volunteers
Study Start Date : August 2009
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Arm Intervention/treatment
Experimental: 1. AZD2423 Drug: AZD2423
oral solution, single dose
Placebo Comparator: 2. Placebo Drug: Placebo
oral solution,single dose

Primary Outcome Measures :
  1. To asses the safety: Adverse events, vital signs, electrocardiograms (ECGs), laboratory variables. [ Time Frame: From screening period to follow-up visit, 40 days (Maximum). ]

Secondary Outcome Measures :
  1. To characterize the pharmacokinetics of AZD2423 in plasma and urine. [ Time Frame: Blood and urine sampling from pre-dose until follow-up visit, 10 days (approximately) ]
  2. Exploratory endpoints;Levels of CCL2 pre-and post dose [ Time Frame: Blood sampling after dosing, 3 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy Japanese male and non-fertile female subjects aged ≥20 to ≤55 years with suitable veins for cannulation or repeated venepuncture.
  • Body weight 45-90 kg and Body mass index (BMI) ≥18.0 and ≤27.0 kg/m2
  • Clinically normal physical findings including supine blood pressure, pulse rate, orthostatic blood pressure, ECG, and laboratory assessments in relation to age, as judged by the Investigator.

Exclusion Criteria:

  • History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  • Any clinically significant illness/infection or medical/surgical procedure or trauma, as judged by the Principal Investigator, within 3 months of the first administration of investigational product.
  • Frequent use of tobacco or other nicotine containing products. Frequent use is defined as smoking or consumption/intake of nicotine products more than two days per week during the last 12 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00970775

United Kingdom
Research Site
Croydon, United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
Principal Investigator: Ulrike Lorch, MD MFPM FRCA Richmond Pharmacology Limited

Responsible Party: MSD, AstraZeneca Identifier: NCT00970775     History of Changes
Other Study ID Numbers: D2600C00003
First Posted: September 2, 2009    Key Record Dates
Last Update Posted: March 18, 2010
Last Verified: March 2010

Keywords provided by AstraZeneca:
Phase I
Japanese healthy volunteer